![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Details:
Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.
Lead Product(s): Mirikizumab-mrkz
Therapeutic Area: Gastroenterology Product Name: Omvoh
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
Mirikizumab is an interleukin-23p19 antagonist that is currently indicated for active ulcerative colitis in Japan, Germany, the United Kingdom and Canada and is being developed for the treatment of adults with moderately to severely active Crohn's disease.
Lead Product(s): Mirikizumab
Therapeutic Area: Gastroenterology Product Name: LY3074828
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
LY3074828 (mirikizumab) is a humanized IgG4 mAb that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for psoriasis, ulcerative colitis and crohn's disease. U.S. FDA has issued complete response letter for mirikizumab.
Lead Product(s): Mirikizumab
Therapeutic Area: Gastroenterology Product Name: LY3074828
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
DES-7114, is an orally administered, highly selective small-molecule inhibitor of the ion channel protein Kv1.3. It has recently completed Phase 1 clinical trials in healthy volunteers and has demonstrated efficacy in preclinical models of inflammatory and autoimmune diseases.
Lead Product(s): DES-7114
Therapeutic Area: Gastroenterology Product Name: DES-7114
Highest Development Status: Phase I Product Type: Small molecule
Recipient: D. E. Shaw Research
Deal Size: $535.0 million Upfront Cash: $60.0 million
Deal Type: Licensing Agreement June 13, 2022
Details:
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for the treatment of immune-mediated diseases, including ulcerative colitis and Crohn's disease.
Lead Product(s): Mirikizumab
Therapeutic Area: Gastroenterology Product Name: LY3074828
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
In the placebo-controlled maintenance cohort, the frequency of serious adverse events among patients treated with mirikizumab was numerically lower compared to placebo, and the overall safety profile was consistent with that of the previous mirikizumab studies in UC.
Lead Product(s): Mirikizumab
Therapeutic Area: Gastroenterology Product Name: LY3074828
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details:
Mirikizumab is being studied for UC and CD, two forms of inflammatory bowel disease that can cause serious and debilitating symptoms, and disruptions in daily life.
Lead Product(s): Mirikizumab
Therapeutic Area: Gastroenterology Product Name: LY3074828
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2021
Details:
Results from the 52-week study showed continued symptom improvement and reduction of intestinal mucosal inflammation in patients with moderately to severely active Crohn's disease after treatment with mirikizumab.
Lead Product(s): Mirikizumab
Therapeutic Area: Gastroenterology Product Name: LY3074828
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020